Top Drug Discovery and Development Companies
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Drug Discovery and Development Companies
Drug Discovery and Development News
Medicine Development Built around Supply Confidence
Friday, September 04, 2026
Shortages in generic and biopharmaceutical medicines rarely begin as a single missed shipment. They build earlier, in product selection, dossier timing, plant readiness, inspection discipline and the handoffs between development teams and commercial supply. Healthcare systems and pharmaceutical partners face more than price exposure. A low-cost product that reaches the market late, produces incomplete regulatory documentation, strains sterile capacity or fails to sustain supply can create treatment gaps that procurement teams cannot correct once contracts are awarded. The buying decision has moved beyond simple generic substitution. Sterile injectables
AI and High-Content Analytics Increase the Value of iPSC Cell Data.
Monday, August 31, 2026
iPSC human cell platforms are seeing stronger demand as AI, high-content imaging and single-cell analysis make human cell data more useful for drug discovery and disease research. The market is no longer only about generating differentiated cells. It is increasingly about extracting interpretable, high-quality biological signals from those cells. Human pluripotent stem cell-derived organoid screening is already evolving to adopt advanced data processing pipelines. The review of human organoids for drug discovery published in 2026 highlighted readout techniques and machine learning technologies that could assist in analyzing complicated organoid systems. The review pointed out th
Cell Therapy Progress Turns iPSC Platforms into Manufacturing Infrastructure.
Monday, August 31, 2026
iPSC human cell platforms are being reshaped by progress in regenerative medicine as developers move from research-grade cell models toward clinical-grade cell products. The market is no longer focused only on making cells for laboratory experiments. It is increasingly tied to GMP manufacturing, cell banking, differentiation protocols and release testing for therapeutic use. Japan has become a visible marker of this transition. Wired reported in 2026 that Japan’s Ministry of Health, Labor and Welfare granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, one for Parkinson’s disease and on
iPSC Human Cell Platforms Move Drug Discovery Closer to Human Biology
Monday, August 31, 2026
iPSC human cell platforms are gaining stronger relevance as pharmaceutical companies look for disease models that better reflect human biology before compounds reach clinical trials. The category is no longer limited to academic reprogramming work. It is becoming a drug-discovery infrastructure layer for disease modeling, toxicity screening, target validation and translational research. Induced pluripotent stem cells allow researchers to generate patient-derived or engineered human cells that can be differentiated into neurons, cardiomyocytes, hepatocytes and other specialized cell types. This creates a way to test compounds in human-relevant systems rather than relying only on
Human Cell Models for Drug Discovery's Next Testing Standard
Monday, August 10, 2026
Drug development is moving toward human biology earlier in the research path, and that shift changes how executives should judge an iPSC human cell platform. The question is no longer whether induced pluripotent stem cells can supply useful models. It is whether a provider can turn them into the right specialized cells with enough biological performance to keep research programs moving. Animal models still carry translational limits, while primary human tissue can be difficult to source and ethically constrained. For neural or cardiac research, buyers need a platform that can offer access to human-relevant cells without making discovery teams depend on scarce donor material. The
Research Peptides Manufacturing Company of the Year
Thursday, June 25, 2026
Executives sourcing research peptides face a market defined by uneven quality signals, limited verification and growing pressure from internal review boards to justify supplier choice. As peptide research expands across cell biology, metabolic studies and regenerative science, variability at the compound level can quietly undermine months of work. The challenge is not access to peptides, but confidence that what enters a protocol is exactly what the specification claims, supported by documentation that withstands institutional scrutiny. Mature buyers increasingly evaluate manufacturers through the lens of verification discipline rather than catalog size alone. Independent analyt
